Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.

Anbok LeeSunmi JoChanghu LeeHyun-Hee ShinTae Hyun KimKi Jung AhnSung-Kwang ParkHeunglae ChoHye-Kyoung YoonWoo Gyeong KimJiyoung ParkYunseon Choi

Published in: Breast cancer (Tokyo, Japan) (2019)

Type 2 diabetes was associated with detrimental effects on survival in postoperative HER-2+ breast cancer patients who were treated with trastuzumab. The poor prognostic effect of diabetes in HER-2+ breast cancer patients could be associated with the high levels of HER-3 and neuregulin 1, thus it should be considered and evaluated more.

Keyphrases

type diabetes
prognostic factors
positive breast cancer
glycemic control
cardiovascular disease
patients undergoing
insulin resistance
epidermal growth factor receptor
adipose tissue
weight loss
free survival
young adults
metabolic syndrome
metastatic breast cancer